Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco
about
A pill for HIV prevention: déjà vu all over again?Preexposure prophylaxis for HIV prevention: where have we been and where are we going?Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challengesPre-exposure prophylaxis for sexually-acquired HIV risk management: a reviewOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesAntiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisChanges in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineBone health in HIV and hepatitis B or C infectionsOsteoporosis in postmenopausal women living with HIVDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life.HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial.PrEP awareness and perceived barriers among single young men who have sex with men.Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Ambiguity, ambivalence, and apprehensions of taking HIV-1 pre-exposure prophylaxis among male couples in San Francisco: a mixed methods study.HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.Effectiveness and safety of oral HIV preexposure prophylaxis for all populationsChallenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in DeliveryLower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.The use of preexposure treatments for HIV prophylaxisEffects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenVitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial.HIV and its effects on bone: a primer for rheumatologistsThe Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.Correlates of PrEP Indication in a Multi-Site Cohort of Young HIV-Uninfected Transgender WomenSymptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.Trabecular and cortical microarchitecture in postmenopausal HIV-infected women.Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individualsPlasmacytoid dendritic cells in HIV infection.What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA PanelHIV PrEP Trials: The Road to Success.The Promise of Antiretrovirals for HIV Prevention.
P2860
Q26824606-140CE7C5-22A3-4227-AEB4-50B1CCFBF875Q26825042-61D0FA7D-C1AE-42E1-A9DD-DD3BDA86AE62Q26825641-91EC5B83-D617-437A-BA63-48731C082FC0Q26849762-F3466C2D-CC6F-47DC-ADD1-5639002B7757Q27023352-88F780F4-7CA4-4805-A58E-4179BDFFF25EQ28085433-5B3A4127-BA37-4941-913C-5185C861109FQ28728374-1DB26C51-A17C-4F92-BA1A-8DD31B98D56FQ30238946-DECA3C00-826B-4A47-8271-BA42FE7F2E05Q30240606-46E3E6EA-F525-47AF-BF42-ED262B6F2913Q30249113-5BF7449C-44FE-45F9-9016-1C88F9DAB5C3Q33603221-A4834242-BD2D-4D7E-91A2-821DA1558DB3Q34046430-160FFE18-A1C7-4FEA-B9BA-1C28B2FA05F9Q34124342-A3F0351E-DD37-495A-AD15-58D6C0113E8AQ34264297-52613AAF-7420-4A0A-9BDF-9F989FDCD5FFQ34380767-9E932780-48AB-451B-9FB7-21227AE1AACBQ34478840-1402866C-EFAE-44C9-A9A3-C2F65C5263F3Q34482984-91C9132D-4619-4A8E-B635-6A3F2EB6CF39Q34673978-D7A45818-3A42-45BA-A036-550BC6A743E5Q34677217-CA23F6A0-6B9C-4B9E-8B7E-CE9E52DF397FQ34968312-40603B13-1B4E-4669-865F-5B790E481B0CQ35119784-2086BA06-7E68-4FAF-BCB9-3611C4325BBFQ35541521-75DC6F00-D31C-4CD4-B5E9-9F583F6239BDQ35659264-347C90E1-FAB8-4AD6-93A6-D855353788F8Q35760180-587B2A3B-EF15-4C98-ADBD-0D9241F00F33Q36048957-B403E3BF-F836-4107-B048-5684B8C28F74Q36070335-90C46FFC-00CE-44F0-BDB1-11E8F590D743Q36170370-54192382-5BA4-4DC2-A54D-E48021D5286EQ36381079-E0408C2F-9D3F-4C83-B487-6F3E30E1E3B4Q36576503-08564F90-DA63-4058-A0DF-15AE9A3D004CQ36584980-20908568-8251-4C67-9A48-DA932C3779FDQ36586078-14705FC7-4144-4A32-853D-F78BBD488C0FQ36649885-CEAD644D-E4D2-45CC-8138-876E3E049B56Q36783183-D31BAF19-980C-420A-AA2D-867CC7B58395Q36849920-C9D99E81-A79F-4424-80D3-7B8F1D161B10Q36958022-447EB9B2-7B3C-428D-9E6A-9ADCE2559E5CQ37019332-3DDEE5A7-3B38-4A50-B6B1-77AB1D109175Q37215398-8A2A0BFA-D37E-4CA5-80A9-B6281801DF4BQ37234729-803A70A9-7258-44A6-9C33-592111B3FE59Q37438644-2DEF76EE-FF57-420E-ADAB-2B6318E8379DQ37511883-789EE4E6-5E1E-4D17-B79E-42267F39D7CE
P2860
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@ast
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@en
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@nl
type
label
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@ast
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@en
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@nl
prefLabel
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@ast
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@en
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@nl
P2093
P2860
P50
P3181
P1433
P1476
Bone mineral density in HIV-ne ...... linical trial in San Francisco
@en
P2093
Albert Y Liu
Brandon O'Hara
Deborah E Sellmeyer
Kata Chillag
Kathleen Mulligan
Lisa Grohskopf
Melanie Thompson
Risha Irvin
Roman Gvetadze
Sonal Pathak
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0023688
P407
P577
2011-01-01T00:00:00Z